The implication is that more agonism is better is going to age very poorly as a default assumption, and any clinician or biohacker still defaulting to it in 2030 is going to look like the cardiologists who were still reaching for first-generation beta-blockers in 1995
stacking Dihexa with cholinergic enhancers is theoretically appealing: Examples: Alpha-GPC, CDP-choline, or acetylcholinesterase inhibitors (ACh-E inhibitors) Rationale: Dihexa enhances synaptic plasticity
By the time a standard glutathione capsule passes through your stomach and enters the small intestine, much of the original molecule has been dismantled
[2] If you have diabetes and cardiovascular risk, this is the oral semaglutide your endocrinologist is most likely to reach for
Free Radic.Biol.Med 7-15-2011;51(2):257-281
The distinction is the whole point: AHK-Cu's defensible, peptide-specific signal is the hair-follicle study